Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. (linkinghub.elsevier.com)

Authors: Janjigian YY … Tabernero J Journal: The Lancet Published: 2026-09-09 DOI: https://doi.org/10.1016/S0140-6736(26)01254-7